Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

Nitesh sinha February 22, 2024
https://ift.tt/n6MIarl

Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation



from Sanofi - Aventis Groupe https://ift.tt/dYZ6OUP
via IFTTT
Tags:
Nitesh sinha

Posted by: Nitesh sinha

Post a Comment

0 Comments

Please ,
Do not enter any kind of span link